Most shareholders never see the document that matters. They see a press release announcing a merger, a board recommendation to vote yes, and a share price that moves on the news. What they do not see is the material fact a board decided to leave out of the proxy. Juan Monteverde has built his legal career around identifying these gaps in corporate disclosures. As the founding partner of Monteverde & Associates PC in New York, Juan E. Monteverde works to improve shareholder awareness, promote market transparency, and address situations where important information may be missing from investor communications.
Market transparency usually gets discussed as a question of regulation: what has to be filed, by when, and in what form. Rules set the floor. Whether the floor holds depends on something else entirely, which is whether anyone is willing to test a company’s disclosures in front of a judge.
Litigation as a Transparency Mechanism
Disclosure obligations are only as strong as the consequences for ignoring them. A board weighing whether to include an unflattering projection, a conflicted banker’s fee arrangement, or a competing offer it declined to pursue is making a practical calculation as much as a legal one. Litigation changes that calculation.
That is the argument Monteverde makes for the role of private plaintiffs in public markets. Well-pleaded cases can be a powerful lever to make companies and their directors candid with the people who own them. A complaint does what no rulebook can: it names the specific omission, demands an explanation, and puts the answer on the record where other investors can read it. Over time, the accumulated record shapes what boards and their advisers treat as standard practice. Much of the shareholder rights litigation filed in New York and Delaware works this way, moving the market’s disclosure baseline case by case rather than through any single dramatic ruling.
The Duty Does Not Wait for a Vote
A common misreading of disclosure law is that it switches on only when a company asks shareholders to do something. Under that view, a proxy solicitation triggers the obligation and quiet periods carry none.
Monteverde’s position is more demanding. Companies and their boards should disclose all material information, whether or not corporate action is being requested. The reasoning is straightforward. Investors make decisions continuously, not only on the days a ballot arrives. They buy, sell, and hold on the basis of what a company has told them, and information a board is sitting on has the same effect on price whether or not a vote is pending. Treating disclosure as an event-driven obligation invites boards to time their candor around their own convenience.
This is also where the practical work of a plaintiff’s firm gets granular. Materiality is contested in almost every case. Establishing it means reconstructing what the board saw, when it saw it, and how a reasonable investor would have weighed it. That is document-level work, and it is the part of the process that rarely makes headlines.
Injunctions, Damages, and Real Consequences
When a company or a board fails to disclose material information, two remedies come into view. Before a transaction closes, a court may enjoin the deal until the record is corrected, which gives shareholders the chance to vote on complete information rather than a curated version of it. After closing, the remedy shifts to damages.
Both matter, and they matter differently. An injunction fixes the immediate problem. A damages award prices the omission, and pricing is what changes behavior at the next company facing the same choice. Firms that concentrate on merger and acquisition litigation tend to be fluent in both, because the available remedy often depends on nothing more than how quickly the omission was found.
Monteverde has pursued that outcome across a series of shareholder matters and as a result is also recognized as a preeminent securities firm listed in the Top 50 in the ISS Securities Class Action Services Report, in recognition of the substantial settlements achieved by Monteverde on behalf of public shareholders. In 2025, Monteverde secured $32.1 million for shareholders in merger class actions, including obtaining a $27.5 million common fund settlement for Aimmune Therapeutics, Inc. stockholders in a class action under Section 14 of the Exchange Act. They also function as public pricing signals about what inadequate disclosure costs or underpays shareholders.
Why Juan Monteverde Frames This as a Market Question
There is a version of shareholder litigation that reads as purely adversarial, a contest between companies and the lawyers who sue them. Monteverde describes the stakes differently. A market that cannot rely on what issuers say has to discount everything they say, and that discount is paid by every shareholder, including those who never file a claim.
His own framing is blunter. His long-stated position is that no one is above the law, and that a corporate title does not come with an exemption from the obligation to tell shareholders the truth. Applied to disclosure, the principle is unglamorous: directors owe candor as a matter of duty, not as a courtesy extended when convenient.
That view is reflected in how Monteverde & Associates PC selects and builds cases, and in a practice that reaches from trial and appellate courts through the United States Supreme Court. It also explains an interest in appellate work, where a single ruling can settle a disclosure standard for an entire circuit rather than one deal.
Transparency as Maintenance, Not Achievement
Market transparency is not a milestone a system reaches and then keeps. It is closer to maintenance work, absorbing pressure from every direction: deal timelines that reward speed, advisers with their own incentives, and the ordinary reluctance to publish information that complicates a recommendation.
Private enforcement is one of the few counterweights that operates continuously rather than in response to scandal. For Juan Monteverde, that is the argument for the work. Each case makes a company explain one specific decision to the shareholders it affected, and the aggregate of those explanations is what a transparent market actually consists of.
The next omission is already being weighed in some boardroom, and the honest answer to whether it gets disclosed depends largely on what happened to the last board that stayed quiet.
